| Bioactivity | Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus[1]. |
| Invitro | Diridavumab (CR6261; 500 μg/mL) 分别以 39.4 μg/mL 和 176.8 μg/mL 的浓度中和 AA60 和 Sw06[1]。 |
| In Vivo | Diridavumab (CR6261; 1.7-15 mg/kg; i.p.; 携带 H2 流感病毒的 BALB/c 小鼠) 以剂量依赖性方式保护小鼠免受致命的 H2 流感病毒的侵害[1]。 Animal Model: |
| Name | Diridavumab |
| CAS | 1393659-46-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91(24):e01603-17. |